These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 3184481)

  • 1. [Clinical course and terminal features of chronic myeloproliferative syndrome].
    Yonemitsu H
    Rinsho Ketsueki; 1988 Jul; 29(7):950-9. PubMed ID: 3184481
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chronic myeloproliferative diseases].
    Verh Dtsch Ges Pathol; 1983; 67():214-75. PubMed ID: 6666266
    [No Abstract]   [Full Text] [Related]  

  • 4. Factor IX activation peptide and soluble selectins in patients with chronic myeloproliferative disorders.
    Cella G; Randi ML; Sbarai A; Bauer KA; Barzega S; Rosenberg RD
    Haematologica; 2002 Jun; 87(6):671-2. PubMed ID: 12031932
    [No Abstract]   [Full Text] [Related]  

  • 5. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome.
    Smalberg JH; Darwish Murad S; Braakman E; Valk PJ; Janssen HL; Leebeek FW
    Haematologica; 2006 Dec; 91(12):1712-3. PubMed ID: 17145613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Platelet function in chronic myeloproliferative syndromes associated with thrombocytosis].
    Grebe G; Pereira J; Mezzano D; Legues ME; Aranda E; Lira P
    Rev Med Chil; 1985 Jan; 113(1):32-7. PubMed ID: 4081383
    [No Abstract]   [Full Text] [Related]  

  • 7. [Blood platelet function in chronic myeloid-type diseases. I. Myeloproliferative diseases].
    Cieslar P; Matousová O
    Vnitr Lek; 1987 Nov; 33(11):998-1009. PubMed ID: 3439041
    [No Abstract]   [Full Text] [Related]  

  • 8. [Platelet defects in chronic myeloproliferative disorders].
    Raszeja-Specht A; Skibowska A; Kabata J; Hellmann A
    Acta Haematol Pol; 1994; 25(3):253-60. PubMed ID: 7992598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases.
    Panteli KE; Hatzimichael EC; Bouranta PK; Katsaraki A; Seferiadis K; Stebbing J; Bourantas KL
    Br J Haematol; 2005 Sep; 130(5):709-15. PubMed ID: 16115126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Histopathology and clinical course of chronic, myeloproliferative diseases].
    Georgii A
    Verh Dtsch Ges Pathol; 1983; 67():214-34. PubMed ID: 6666265
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders.
    Passamonti F; Vanelli L; Malabarba L; Rumi E; Pungolino E; Malcovati L; Pascutto C; Morra E; Lazzarino M; Cazzola M
    Haematologica; 2003 Oct; 88(10):1123-9. PubMed ID: 14555308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relationship between microvascular occlusion-like symptoms and spontaneous platelet aggregation in chronic myeloproliferative diseases (author's transl)].
    Tanoue K; Nakazawa M; Nakamura H; Nagasawa T; Yoda Y; Abe T; Ijima H; Iyori S
    Rinsho Ketsueki; 1981 Jul; 22(7):1123-9. PubMed ID: 7328769
    [No Abstract]   [Full Text] [Related]  

  • 13. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England.
    Phekoo KJ; Richards MA; Møller H; Schey SA;
    Haematologica; 2006 Oct; 91(10):1400-4. PubMed ID: 17018393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complications and conversions in myeloproliferative disorders: an analysis of 356 cases.
    Wang Y; Zuo A; Liu Y; Liu B; Hao C; Wang L; Zhou X; Qian L
    Zhonghua Xue Ye Xue Za Zhi; 2002 Jun; 23(6):314-7. PubMed ID: 12411064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Indices of cellular and humoral immunity in chronic myeloproliferative diseases].
    Vygovskaia IaI; Loginskiĭ VE; Mazurok AA; Shnitsar ZV
    Ter Arkh; 1986; 58(9):93-6. PubMed ID: 3491438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.
    Radin AI; Kim HT; Grant BW; Bennett JM; Kirkwood JM; Stewart JA; Hahn RG; Dutcher JP; Wiernik PH; Oken MM;
    Cancer; 2003 Jul; 98(1):100-9. PubMed ID: 12833462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Unusual case of chronic myeloproliferative syndrome].
    Tosato F; Fossaluzza V
    Arch Sci Med (Torino); 1982; 139(4):531-5. PubMed ID: 6891999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [So-called primary (idiopathic) osteomyelofibrosis/-sclerosis (OMF) within the scope of chronic myeloproliferative diseases. II. Course and therapy in 102 patients with special reference to early hyperplastic and advanced fibrosclerotic stages].
    Zankovich R; Thiele J; Mödder B; Steinberg T; Simon KG; Fischer R; Diehl V
    Med Klin (Munich); 1988 Oct; 83(19):629-36. PubMed ID: 3185421
    [No Abstract]   [Full Text] [Related]  

  • 19. [Isolation of size-dependent human platelet subpopulations. I. The method for isolation of size-dependent platelet subpopulations by counterflow centrifugal elutriation].
    Saigo K; Ryo R; Nakaya Y; Yamaguchi N; Ryo R; Saigo K; Ueda K
    Rinsho Byori; 1986 Oct; 34(10):1159-62. PubMed ID: 3807001
    [No Abstract]   [Full Text] [Related]  

  • 20. ABO blood group does not increase the risk of thrombosis in Philadelphia-negative myeloproliferative disorders.
    Moreno MJ; Lozano ML; Ferrer F; Bellosillo B; Besses C; Vicente V; Martínez C
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):390-2. PubMed ID: 19542939
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.